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Abstract: Drugs of abuse induce plastic changes in the brain that seem to underlie 
addictive phenomena. These plastic changes can be structural (morphological) or synaptic 
(biochemical), and most of them take place in the mesolimbic and mesostriatal circuits. 
Several addiction-related changes in brain circuits (hypofrontality, sensitization, tolerance) 
as well as the outcome of treatment have been visualized in addicts to psychostimulants 
using neuroimaging techniques. Repeated exposure to psychostimulants induces 
morphological changes such as increase in the number of dendritic spines, changes in the 
morphology of dendritic spines, and altered cellular coupling through new gap junctions. 
Repeated exposure to psychostimulants also induces various synaptic adaptations, many of 
them related to sensitization and neuroplastic processes, that include up- or  
down-regulation of D1, D2 and D3 dopamine receptors, changes in subunits of G proteins, 
increased adenylyl cyclase activity, cyclic AMP and protein kinase A in the nucleus 
accumbens, increased tyrosine hydroxylase enzyme activity, increased calmodulin and 
activated CaMKII in the ventral tegmental area, and increased deltaFosB, c-Fos and AP-1 
binding proteins. Most of these changes are transient, suggesting that more lasting plastic 
brain adaptations should take place. In this context, protein synthesis inhibitors block the 
development of sensitization to cocaine, indicating that rearrangement of neural networks 
must develop for the long-lasting plasticity required for addiction to occur.  
Self-administration studies indicate the importance of glutamate neurotransmission in 
neuroplastic changes underlying transition from use to abuse. Finally, plastic changes in 
the addicted brain are enhanced and aggravated by neuroinflammation and neurotrophic 
disbalance after repeated psychostimulants. 
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1. Introduction 
The term neuronal plasticity, in wide sense, refers to the neurobiological basis that allows adaptive 
changes in behavior, motivation and emotions, and it is also on the basis of maladaptive changes 
related to addictive phenomena [1]. Two types of neuroplasticity can be distinguished: structural 
plasticity and synaptic plasticity. Structural plasticity refers to changes in neuronal morphology 
(including axons, dendrites and dendritic spines), the genesis and suppression of synapses, and the 
genesis of new neurons (neurogenesis) and neurites (neuritogenesis). Synaptic plasticity refers to 
biochemical and neurochemical modifications related to changes in synaptic activity, which leads to 
enduring changes in synaptic efficacy, and in behavior accordingly. Other addiction-related processes 
are associated with neuroplasticity, for instance drug sensitization, self-administration, drug-seeking 
and hypofrontality. These phenomena have been analyzed in depth, mostly in relation to repeated 
psychostimulants, during the last years. 
Addictive drugs of abuse have the potential to induce addiction through enduring changes in 
neuronal plasticity, altering neurotransmission systems, the strength and duration of synaptic contacts, 
neuronal morphology, etc. In other terms, addiction is a disease whose neuropathology is based on 
aberrant structural and synaptic plasticity. By changing brain circuits, addictive drugs impair the 
development of behavioral strategies towards biological stimuli in favor of progressively greater 
orientation of behaviors towards drug seeking and drug-taking strategies. Enduring drug-induced 
neuroplasticity establishes a maladaptive orientation to the environment that manifests as: i) impaired 
ability to regulate the drive to obtain and use drugs, and ii) reduced drive to obtain natural rewards. 
Psychostimulant drugs such as amphetamine and cocaine are prototypic drugs inducing neuroplasticity 
changes, and they have been extensively studies during the last years.  
2. Sensitization, a Model of Neural Plasticity 
The repeated administration of drugs of abuse such as cocaine and amphetamine produces a 
progressive increase in locomotor activity over time, referred as motor sensitization. Motor 
sensitization is considered as a model of neural plasticity [2-4], and neuroadaptations mediating 
sensitization could underlie some of the behavioral changes associated with chronic drug abuse [5]. 
Chronic psychostimulant exposure produces biochemical adaptations in specific brain regions thought to 
mediate activating properties of these drugs [3,6]. The mesolimbic system is the most important system 
involved in these adaptations, which comprises dopaminergic neurons in the ventral tegmental area 
(VTA) and their projections to the limbic forebrain such as the nucleus accumbens [3,7]. Other structures 
such as prefrontal cortex, amygdala and hippocampus are also involved. Recently Perez et al. [8] 
reported that sensitization to cocaine generates a high efficiency of hippocampal synaptic plasticity 
that may underlie the aberrant engagement of learning processes occurred during drug addiction. 
At a biochemical level, tyrosine hydroxylase (TH) and N-methyl-D-aspartate receptor 1 
(NMDAR1) expression in the VTA are found to be increased after repeated psychostimulant and other 
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drugs of abuse [9-12], and these changes are known to be related to motor sensitization. Thus TH  
up-regulation leads to augmented dopamine neurotransmission in the VTA and nucleus accumbens [9,10], 
a critical feature for the development of sensitization. Repeated drug exposure is known to increase 
extracellular dopamine levels in the nucleus accumbens [13,14], and acute or chronic cocaine directly 
induces augmentation of dopamine release in the nucleus accumbens. Repeated cocaine exposure also 
leads to down-regulation of D2 receptors in the ventral tegmental area, together with sensitization of 
D1 receptors located to the glutamatergic terminals of the VTA, all together inducing an augmented 
dopaminergic activity in this area as well [3,15-18]. NMDA receptors become more permeable to 
calcium after chronic cocaine’s administration, another critical feature in the motor sensitization 
process [19]. D1 receptors of the nucleus accumbens become upregulated during sensitization, and 
infusion of a D1R agonist into this nucleus are known to enhance cocaine-induced behavioural 
sensitization [20]. NMDARs are located on non-DA neurons within the VTA and they play a major 
role in cocaine-induced sensitization addictive behavior [21]. 
The endocannabinoid system is also involved in sensitization processes to psychostimulants. The 
brain contains an endogenous cannabinoid system that participates in several processes such as 
nociception, emotion, motor control, and reward [22]. The endocannabinoid system and CB1 receptors 
(CB1Rs) are involved not only in the reinforcement properties of ∆9-tetrahydrocannabinol [23], but 
also of several drugs of abuse such as cocaine [24]. The overall picture is that cannabinoid CB1R 
appear to be involved in the persistence of cocaine addiction [25], affecting the expression, not 
induction, of sensitization. Thus, systemic injections of rimonabant, ligand of CB1 receptors with 
rimonabant does not affect the development of cocaine’s sensitization in rats [26], but the expression 
of cocaine’s sensitization has been reported to be reduced by pretreatment with rimonabant [27,28]. 
Silencing accumbal CB1R with siRNAs (using lentiviral-mediated silencing of CB1R) leads to strong 
increase in motor activating effects of cocaine, and motor sensitization is not affected  
(unpublished results). 
Our studies indicate that, at the level of the ventral tegmental area, D-serine, an endogenous ligand 
of the glutamatergic NMDA receptor, is involved in sensitization effects of psychostimulants [29]. 
Astrocytes and neurons express D-amino acid oxidase (DAO, synthesizing enzyme for D-serine) and release 
D-serine [30-32]. D-serine modulates NMDA receptor activity in the central nervous system [33-35], and it 
acts through binding to NMDA receptors at the glycine site, thereby facilitating their activation [25]. 
In this context, sensitization-related changes in the VTA have been compared to long-term potentiation 
(LTP) in the hippocampus. Besides it is known that a single injection of cocaine can induce LTP of 
AMPA receptor-mediated current in dopaminergic neurons in the VTA [36]. Stimulation of NMDA 
receptors is needed for the development of cocaine’s sensitization [37-39]. The NMDA receptor 
consists of several distinct binding sites identified by the ligand: glutamate or NMDA, PCP or  
MK-801, glycine, as well as Mg2+-binding site. D-Serine and glycine are co-agonists with glutamate 
for the NMDA receptor ionophore [40], and co-agonism in the VTA is needed for the initiation of 
locomotor sensitization to cocaine.  
Sensitization is also mediated by calcium and calmodulin-kinase II (CaMKII) signaling in the 
ventral tegmental area. Thus, enhanced levels of calcium in the VTA mediate locomotor activating 
effects of cocaine [16,18]. Glutamatergic AMPA and NMDA receptors along with L-type calcium 
channels are involved in these activating effects, because they become more permeable to calcium 
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after cocaine’s administration [18]. Calcium binds calmodulin (calcium/CaM complex) and then 
calcium-dependent kinases such as CaMKII bind calcium/CaM become phosphorylated and activated 
by calmodulin kinase-kinase (CaMKK). It is well known that cocaine injections enhance total CaMKII 
protein in the VTA [39]. Suppressing CaMKII activity in the ventral tegmental area enhances the acute 
response to 15 mg/kg cocaine, and attenuates the initiation of cocaine-induced behavioral sensitization 
in rats [39]. CaMKII is a transducer of calcium signaling, this kinase being expressed in many brain 
regions [41,42], including the VTA [39]. Calcium signaling pathways play a pivotal role in synaptic 
plasticity and memory formation [43,44], as well as CaMKII [45]. CaMKII functions as a potent 
stimulator of calcium-dependent gene expression, and it activates several transcription factors such as 
CREB, which is phosphorylated on the regulatory Ser133 residue [46,47]. CREB activation in the 
VTA is directly involved in sensitization as explained, and regulates tyrosine hydroxylase (TH) 
transcription [48]. 
3. Structural Plasticity after Psychostimulant Consumption 
Repeated exposure to psychostimulants induces morphological changes in the mesolimbic target areas 
such as increase in the number of dendritic spines, changes in the morphology of dendritic spines, and 
altered cellular coupling through new gap junctions [49-51]. Several experimental data suggest that 
rearrangement of neural networks must develop for the long-lasting plasticity required for sensitization 
to occur. Protein synthesis inhibitors block the development of sensitization to cocaine [52], and pups 
younger than three weeks old, which are too immature to develop neural networks, do not become 
sensitized to psychostimulants [53]. Hence sensitization is also linked to morphological changes in 
rewarding circuits. 
Arc mRNA and Arc protein, markers for neuritic outgrowth, have been reported to be upregulated in 
the dorsal striatum after chronic cocaine in rats [54], and downregulation of mielin-related genes takes 
place in the nucleus accumbens of human cocaine abusers [55]. Enhancement of deltaFosB and AP-1 
proteins has been postulated to subserve these morphological changes [3]. In fact, the transcription factor 
deltafosB accumulates in dopamine-terminal fields in the cortex and striatum [3,56], and it is a strong 
candidate for mediating enduring changes in these regions. In fact, increase in dendritic spine density has 
been reported in accumbens spiny neurons during extended abstinence from psychostimulants [57], and 
this increase is mediated by deltaFosB stimulation of Cdk5 [51]. 
Another change in protein synthesis that is particularly important in establishing drug-induced 
neuroplasticity is a rise in brain-derived neurotrophic factor (BDNF). The enduring changes in BDNF 
accumulate with increasing period of abstinence [27,58,59], and BDNF promotes forms of synaptic 
plasticity such as dendritic spine formation [60]. This protein is another stable neuroplasticity 
candidate that may contribute to persistence of addiction and drug-seeking behavior. 
It is of great interest that similar neuroplastic changes take place in different reinforcement-related 
behaviors. Thus repeated sexual behavior induces a sensitized locomotor response to amphetamine in 
rats, and the number of dendrites and spines in the nucleus accumbens is increased with sexual 
experience. Sexual experience induces functional and morphological alterations in the mesolimbic 
system similar to repeated exposure to psychostimulants, hence some alterations in the mesolimbic 
system are common for natural and drug reward and might play a role in general reinforcement [61]. 
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4. Self-Administration and Neuroplasticity 
There is an important literature on the neuroplastic changes at excitatory synapses in the brain 
reward circuits associated with psychostimulant self-administration in rodent, an experimental model 
which is much more likely to help understanding the neural basis of drug addiction. In fact, several 
studies have demonstrated that voluntary drug intake through a self-administration paradigm induce 
different changes to those observed after non-contingent drug-exposure [62-65]. Self-administration 
studies indicate that cocaine induces an enhancement of glutamatergic function in VTA dopamine 
neurons. This effect of cocaine is not by itself because it is necessary a strong pairing between the drug 
and a cue, pointing to the great importance of conditioned responses for synaptic plasticity after drugs 
of abuse [65]. Glutamate receptors such as mGlu5 receptors are involved in cocaine-induced plasticity 
in VTA dopaminergic cells, but mGlu5 receptor may not be essential for psychostimulant behavioural 
sensitization and consolidation of addiction [66].  
In this context, the nucleus accumbens and its NMDA receptors, another type of glutamate 
receptors, are more involved in persistent addiction, through the modulation of long term depression 
(LTD), a form of synaptic plasticity. Kasanetz et al. [67] have suggested that a failure of an individual 
to counteract the impairment in NMDAR-LTD after chronic cocaine contributes to the transition to 
addiction. Self-administration studies also indicate that AMPA receptors in the nucleus accumbens are 
involved in cocaine-seeking after addiction consolidation. Thus the number of AMPA receptors in the 
nucleus accumbens is increased after prolonged abstinence from cocaine self-administration. New 
AMPA receptors lacking glutamate receptor 2 (GluR2) are added, and these receptors mediate the 
incubation of drug craving [68]. All these studies strengthen the concept than transition from use to 
abuse takes place in limbic structures such as the nucleus accumbens and that glutamate 
neurotransmission is associated to plastic changes mediating this transition and craving responses 
during withdrawal. 
5. Neuroimaging and Psychostimulants 
Addiction-related changes in cortical circuits has been visualized in addicts to psychostimulants 
using neuroimaging techniques. These studies indicate that there is a reduction in prefrontal cortex 
(PFC) metabolism and blood flow in addicted to cocaine [69]. This “hypofrontality” is a strong 
indicator of reduced ability to regulate drug-seeking or to inhibit motivational drives related to drug 
addiction, because affected regions are anterior cingulate and ventral orbital cortex, which are strongly 
linked to motivated behavior, switching and attention responses [70,71]. D2 dopamine receptor 
functionality seems to be linked to this hypofrontality, as suggested by Volkow et al [72]. These 
authors observed that there is an association between level of dopamine D2 receptors, and metabolism 
in the orbitofrontal cortex in methamphetamine and cocaine abusers. They propose that D2  
receptor-mediated dysregulation of the orbitofrontal cortex could underlie a common mechanism for 
loss of control and compulsive drug intake in drug-addicted subjects. Furthermore, if addicted subjects 
are exposed to cues previously associated to the drug, there is a marked activation in the prefrontal 
cortex [69,73]. The activity in the PFC has been positively correlated with the intensity of cue-induced 
desire for the drug, an index for craving. 
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Psychostimulants induce dopamine release in ventral and dorsal striatal nuclei. Thus Willeit et al. [74] 
have observed that D-amphetamine induces displacement of the D2/3 agonist radioligand  
[11C]-(+)-4-propyl-9-hydroxynaphthoxazine [(+)-PHNO], a neuroimaging way to measure dopamine 
release in the living human brain. Sensitization to amphetamine has also been modeled using 
neuroimaging by Boileau et al [75]. Thus they report that an initial dose of amphetamine causes 
dopamine release in the ventral striatum, as evaluated by the reduction in [11C]raclopride binding. 
Consistent with a sensitization-like phenomenon, 14 and 365 days after the third dose of amphetamine 
there is a greater psychomotor response and increased dopamine release (a greater reduction in 
[11C]raclopride binding), relative to the initial dose, in the ventral striatum, progressively extending to 
the dorsal caudate and putamen. This phenomenon persists for at least one year.  
Neuroimaging techniques have also revealed that there is a reduction in dopamine receptor 
activation in response to low doses of psychostimulants [76,77]. Methylphenidate-induced dopamine 
release into the striatum is impaired in cocaine addicts, and addicts show reduced levels of D2 
receptors in the striatum [78]. Subjects with low D2 density report pleasurable effects from 
methylphenidate, whereas subjects with higher D2 density do not like the effects of this 
psychostimulant drug [79]. The binding of cocaine and other psychostimulants to DAT can be assessed 
in humans by measuring the dose-dependent displacement of [11C]cocaine by a non-radiactive 
competitor. The extent of euphoria experienced following administration of cocaine correlated 
positively with the occupancy of [11C]cocaine-binding sites in the striatum, and all subjects with 
greater than 60% occupancy of DAT experienced euphoria [80]. 
Neuroimaging studies confirm that cocaine and methamphetamine abuse induce down-regulation of D2 
receptors, and this downregulation wears off after prolonged abstinence. Thus in chronic cocaine users, 
[11C]raclopride is reduced by 15% in the striatum [81], and simple ratio of [11C]NMSP uptake in the 
striatum is also reduced, but returns to normal after prolonged abstinence [82]. Regarding 
methamphetamine abusers, it has been detected a 10-15% reduction in striatal [11C]raclopride binding [72]. 
Finally, treatment response in cocaine abusers is related to dopamine signaling as recently 
demonstrated by Martinez et al. [83], who have reported that low dopamine transmission is associated 
with treatment failure. Thus they quantified, prior to treatment, [11C]raclopride binding before and 
after the administration of methylphenidate, and the outcome measures were lower in the volunteers 
who did not respond to treatment than in those who experienced a positive treatment response. The 
authors propose that the combination of behavioral treatment with methods that increase striatal 
dopamine signaling might serve as a therapeutic strategy for cocaine dependence [83]. 
6. Psychostimulants and Neuroinflammation 
Neuroinflammation of the central nervous system seems to participate in neuroplasticity changes 
and sensitizing effects of drugs such as psychostimulants [84-86]. It worth recalling that inflammation 
is part of a complex biological response to harmful stimuli, such as pathogens or irritants. Drugs of 
abuse could be included among irritants, and neuroinflammation would be a protective attempt by the 
organism to remove the injurious stimuli. In this context, it is well known that psychostimulants 
enhance activation of inflammatory cells such as astrocytes and glial cells in neocortex [87]. Activated 
astrocytes and glia release numerous pro-inflammatory factors such as nitric oxide, ATP, TGF-α, 
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interleukin-1β, interleukin 2 and interleukin 6 [88-90], and several inflammatory cytokines such as 
interferon-gamma and interleukin 10 are enhanced by chronic cocaine [91]. Cocaine is also known to 
enhance the transcription factor nuclear factor-kappaB (NF-κB), and it reduces levels of TNF-α [92]. 
In this context, NF-κB is an important inflammatory factor that controls many genes involved in 
inflammation, and NF-κB is found to be chronically active in many inflammatory diseases.  
Apart from proinflammatory factors released by astrocytes and glia, it is of interest that peroxisome 
proliferator-activated receptors (PPARs) are involved in neuroinflammation and drug dependence, 
because PPAR-γ has a significant role in the expression of motor sensitization to metamphetamine in 
mice [86]. Peroxisome proliferator-activated receptor is a ligand-activated transcription factor 
belonging to a nuclear hormone receptor superfamily. Three PPAR isotypes (α, β, γ) have been 
characterised and can be translocated to the nuclear fraction of cells as heterodimers with the retinoid 
X receptor (RXR). The ligand-activated heterodimers can bind to PPAR response element (PPRE) to 
regulate the transcription of target genes. Inflammation is known to be regulated by PPAR-γ and 
PPAR-α, whose activation negatively regulates the transcription of inflammatory response genes by 
antagonizing the AP-1 and NF-κB signalling pathways [93-95]. In fact, PPARs play prominent roles in 
several physiological processes including the inflammatory response apart from their role in the 
control of lipid and lipoprotein metabolism, and glucose homeostasis [96-98]. Recently we have 
observed that PPAR-α plays a homeostatic role attenuating motor sensitizing effects of repeated 
morphine treatment, but not cocaine, likely through a reduction of inflammation-associated changes [99]. 
It seems that, among PPARs, PPAR-γ but not PPAR-α, is more involved in sensitizing effects of 
psychostimulants. However it is worthnoting that PPAR-α has been linked to the reinforcing effects of 
some drugs such as nicotine, because PPAR-α agonists supress nicotine-induced activation of 
mesolimbic dopamine neurons through PPAR-α [100]. 
7. Psychostimulants and Altered Neurotrophism 
The emergence of neurotrophic disbalance, mainly within the mesolimbic regions and other regions 
such as amygdala and hippocampus, seems to be important in the development of addictive processes 
and neuroplastic changes after psychostimulants and other drugs of abuse. Neurotrophic factors have 
been implicated in many forms of plasticity in the adult nervous system, hence changes in dopamine 
systems after repeated drugs suggest that neurotrophic factors such as GDNF, BDNF or FGFs are 
involved in drug’s addictive processes [3,9,101-106]. 
Among these trophic factors, fibroblast growth factors (FGFs) and their receptors participate in 
many processes such as regulation of synaptic plasticity, learning and memory [107], and FGF-2 
(fibroblast growth factor-2) has been involved in the sensitizing effects of psychostimulants [105,106]. 
Fibroblast growth factor-1 or FGF-1, another member of the FGFs family, is also involved in the 
regulation of synaptic plasticity [107], and it is implicated in sensitization to drugs of abuse [108]. 
Fumagalli et al. [109] have demonstrated that stress interacts with cocaine to alter the pattern of FGF-2 
expression in a regionally selective fashion. These results identify a potential molecular target through 
which stress alters cellular sensitivity to cocaine and might prove useful in understanding the 
mechanisms underlying brain vulnerability to stress. 
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At the level of ventral tegmental area, deficit of GDNF and upregulation of neurotrophins such as 
NT-3 are linked to sensitization phenomena after psychostimulants. This dual change represents quite 
well the emergence of a neurotrophic disbalance during addiction, because both GDNF dowregulation 
and NT-3 upregulation facilitates dopamine activity within the VTA. GDNF is released by dopamine 
neurons of VTA acting retrogradely on GABAergic terminals enhancing GABA release after 
enhancement of the calcium binding protein frequenin inside terminals [110]. Downregulation of 
GDNF leads to a higher activity of dopamine neurons that as a consequence are subjected to less 
inhibition from GABAergic interneurons. 
As already mentioned, another change in protein synthesis that is particularly important in 
establishing drug-induced neuroplasticity is a rise in brain-derived neurotrophic factor (BDNF). 
Changes in levels of BDNF protein and mRNA have been observed in the brain following 
administration of drugs of abuse such as psychostimulants, and these changes have been observed in 
the nucleus accumbens, prefrontal cortex, ventral tegmental area, and amygdala [111-114]. BDNF 
signaling can induce different effects depending on the brain region examined. For instance, increased 
BDNF in the NAc enhances cocaine-induced behaviors [113], whereas in the prefrontal cortex BDNF 
supresses them [115]. Besides BDNF infused into the hippocampus is antidepressant, but in the 
nucleus accumbens exerts prodepressant effects. In the medial prefrontal cortex, upregulated BDNF 
facilitates LTP and contributes to neurobehavioral adaptations to psychostimulants [116].  
Cortico-tegmental BDNF is also involved in long-term amphetamine sensitization [117]. 
Calcium influx and CaMKII have been also implicated in the production and responsiveness to  
BDNF [118,119]. BDNF participates on the development of sensitization to cocaine or amphetamine 
because direct infusion of BDNF into the VTA blocks the ability of cocaine to produce some biochemical 
and morphological effects in this region, such as the induction of tyrosine-hydroxylase [9,101], and 
repeated amphetamine treatment increases BDNF within the VTA, an effect that is enhanced in 
sensitized animals [117]. BDNF also participates during abstinence, and recently it has been observed 
that elevated BDNF expression after cocaine withdrawal sensitizes the excitatory synapses in the 
medial prefrontal cortex, and this fact may contribute to cue-induced drug craving and drug-seeking 
behavior [116]. In the medial prefrontal cortex, upregulated BDNF facilitates LTP and contributes to 
neurobehavioral adaptations to psychostimulants. 
8. Conclusions 
Psychostimulants induce plastic changes in the brain that seem to underlie addictive phenomena. 
These plastic changes take place in the mesolimbic and mesostriatal circuits. Several addiction-related 
changes in brain circuits (hypofrontality, sensitization, morphological alterations) as well as the 
outcome of treatment have been visualized in addicts to psychostimulants using neuroimaging 
techniques. Repeated exposure to psychostimulants induces morphological changes such as increase in 
the number of dendritic spines or changes in the morphology of dendritic spines. Besides repeated 
exposure to psychostimulants also induces various synaptic adaptations, many of them related to 
sensitization and neuroplastic processes, that include up- or down-regulation of D1, D2 and D3 
dopamine receptors, changes in subunits of G proteins, increased adenylyl cyclase activity, cyclic 
AMP and protein kinase A in the nucleus accumbens, increased tyrosine hydroxylase enzyme activity, 
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increased calmodulin and activated CaMKII in the ventral tegmental area, and increased deltaFosB,  
c-Fos and AP-1 binding proteins. Most of these changes are transient, suggesting that more lasting 
plastic brain adaptations should take place. Self-administration studies indicate the importance of 
glutamate neurotransmission in neuroplastic changes underlying transition from use to abuse. Finally, 
plastic changes in the addicted brain are enhanced and aggravated by neuroinflammation and 
neurotrophic disbalance after chronic psychostimulant administration. 
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